LP-168 / Lupeng Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LP-168 / Lupeng Pharma
NCT05716087: A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma

Recruiting
2
62
RoW
LP-168, NWP-775
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
02/24
12/25

Download Options